Simple Summary Chronic myeloid leukaemia (CML) is a type of blood cancer that is
currently well-managed with drugs that target cancer-causing proteins. However, a …

The gut microbiota has recently been proposed as a novel component in the regulation of
host homeostasis and immunity. We have assessed for the first time the role of the gut …

For patients with chronic myeloid leukemia who become or are inherently resistant to
imatinib therapy, including dose escalation, several important factors must be considered …

One of the characteristics that distinguish anticancer agents from other drugs is the
frequency and severity of side effects at therapeutic doses. Most cytotoxic drugs target …

We tested the hypothesis that changing the gut microbiota using pectic oligosaccharides
(POS) or inulin (INU) differently modulates the progression of leukemia and related …

Simple Summary Chronic myeloid leukemia is a type of blood cancer that is regarded as a
success story in determining the exact biological origin, pathogenesis and development of a …

Chronic myeloid leukemia (CML) results from expression of the constitutive tyrosine kinase
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …

Objective: To determine the frequency of three phases of chronic myeloid leukaemia at first
presentation. Study Design: Case series. Place and Duration of Study: Department of …

Peroxisome proliferator‐activated receptor gamma (PPARγ) is a multifunctional transcription
factor with important regulatory roles in inflammation, cellular growth, differentiation, and …

Sphingomyelin synthase (SMS) produces sphingomyelin while consuming ceramide (a
negative regulator of cell proliferation) and forming diacylglycerol (DAG)(a mitogenic factor) …